Attovia Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Attovia Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Attovia Therapeutics, Inc. Common Stock (ATTO) has a cash flow conversion efficiency ratio of -0.149x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.79 Million) by net assets ($112.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Attovia Therapeutics, Inc. Common Stock (2024–2025)
Cash flow conversion efficiency of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Attovia Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Attovia Therapeutics, Inc. Common Stock for real-time trading data and today's change.
Attovia Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Attovia Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Attovia Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Attovia Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see ATTO company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fujian Nebula Electronics Co Ltd
SHE:300648
|
0.006x |
|
Sinopec Oilfield Equipment Corp
SHE:000852
|
0.108x |
|
Pilkington Deutschland AG
HM:FDD
|
N/A |
|
Guangdong Kinlong Hardware Products Co Ltd
SHE:002791
|
0.031x |
|
Vital Energy Inc.
NYSE:VTLE
|
0.163x |
|
Tong Oil Tools
SHE:300164
|
0.020x |
|
Jinxi Axle Co Ltd
SHG:600495
|
-0.015x |
|
Beijing Join-Cheer Software Co Ltd
SHE:002279
|
0.064x |
Annual Cash Flow Conversion Efficiency for Attovia Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Attovia Therapeutics, Inc. Common Stock from 2024 to 2025. Review ATTO financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $150.79 Million | $-59.20 Million | -0.393x | +30.38% |
| 2024-12-31 | $62.13 Million | $-35.03 Million | -0.564x | -- |
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of… Read more